Clinical Trial Update: Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing the efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer, stratified by TP53 mutational status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Non Small Cell Lung Cancer | Phase 4 | Status: UNKNOWN